Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
320
Trial Sponsor
Clinical Trial Start Date
February 24, 2024
0Primary Completion Date
September 30, 2027
0Study Completion Date
September 30, 2042
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Interventional Trial Phase
Phase 10
Participating Facility
Official Name
A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus0
Last Updated
March 13, 2024
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Other attributes
Intervention Treatment
Fludarabine0
FT8190
Cyclophosphamide0
Bendamustine0
Study summary
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following conditioning chemotherapy in participants with moderate to severe active systemic lupus erythematosus (SLE). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
